News articles about Sage Therapeutics (NASDAQ:SAGE) have trended somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sage Therapeutics earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.5245976861864 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Several research firms recently commented on SAGE. Needham & Company LLC set a $95.00 price target on shares of Sage Therapeutics and gave the company a “buy” rating in a research note on Friday, August 4th. HC Wainwright upped their price target on shares of Sage Therapeutics to $86.00 and gave the company a “neutral” rating in a research note on Friday, August 4th. Cowen and Company restated a “buy” rating and issued a $100.00 price target on shares of Sage Therapeutics in a research note on Friday, August 4th. Stifel Nicolaus began coverage on shares of Sage Therapeutics in a research note on Wednesday, August 9th. They issued a “buy” rating and a $104.00 price target on the stock. Finally, Canaccord Genuity set a $110.00 price target on shares of Sage Therapeutics and gave the company a “buy” rating in a research note on Saturday, August 5th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $86.77.

Shares of Sage Therapeutics (SAGE) opened at 64.69 on Thursday. The firm’s market capitalization is $2.42 billion. The firm’s 50-day moving average is $73.93 and its 200-day moving average is $74.46. Sage Therapeutics has a 52 week low of $38.30 and a 52 week high of $90.80.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by ($0.25). During the same quarter in the previous year, the company posted ($1.08) earnings per share. Equities analysts anticipate that Sage Therapeutics will post ($7.37) EPS for the current year.

WARNING: “Sage Therapeutics (SAGE) Receiving Somewhat Positive Press Coverage, Study Shows” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/10/05/sage-therapeutics-sage-receiving-somewhat-positive-press-coverage-study-shows.html.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Insider Buying and Selling by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.